Status:
COMPLETED
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Parkinson Disease
Eligibility:
All Genders
Brief Summary
The purpose of the study is to investigate the incidences of psychiatric symptoms (example, hallucinations), somnolence and sudden onset of sleep, dyskinesia, and retinal degeneration-related events d...
Eligibility Criteria
Inclusion
- 1\. Participants with Parkinson's disease, who are naïve to Equfina
Exclusion
- Participants previously treated with Equfina
- Participants who have contraindications on package insert of Equfina
Key Trial Info
Start Date :
October 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2022
Estimated Enrollment :
1088 Patients enrolled
Trial Details
Trial ID
NCT04724109
Start Date
October 14 2020
End Date
October 13 2022
Last Update
December 16 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Eisai Trial Site 2
Osaka, Japan
2
Eisai Trial Site 1
Tokyo, Japan